# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Irène Joliot-Curie (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-RB003-SYN-TD
- Date: 1955-10-19
- Fictional facility: St. Posthumous Health Center
- Fictional author: Solène Marchand-Ellis, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Day 22 of cycle 1: bone marrow response and count recovery. **S**

## History of present illness

Mrs. Joliot-Curie returns on day 22 of her first cycle. She spent five days in hospital for the ramp-up without tumor lysis. The nausea and constipation of the second week settled within three days on ondansetron and laxatives, and she has needed no ondansetron for a week. She has had no fever. She had one more unit of red cells and one dose of platelets on day 11 and none since. She had her bone marrow biopsy this morning. She has met the palliative care team again and the transplant center once. Her dose records have not yet arrived. **S**

| Element | Detail |
|---|---|
| Cycle | Day 22 of cycle 1 of azacitidine with venetoclax 70 mg daily |
| Side effects | Nausea and constipation settled; no fever or infection |
| Transfusions | One unit of red cells and one dose of platelets on day 11 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; no fever or chills |
| Ears, nose, mouth, and throat | Negative | No mouth sores or sore throat |
| Respiratory | Negative | No cough; breathless on stairs as before |
| Gastrointestinal | Negative | No nausea, diarrhea or constipation now |
| Integumentary | Negative | No new bruises or rash |

5 systems reviewed. **S**

## Current medications

- Azacitidine 115 mg (75 mg/m2) under the skin once daily on days 1 to 7 of each 28-day cycle **S**
- Posaconazole 100 mg delayed-release tablet, three tablets (300 mg) twice on day 1, then three tablets once daily, as antifungal prophylaxis while neutropenic **S**
- Acyclovir 400 mg oral tablet, one tablet twice daily as herpes simplex and zoster prophylaxis **S**
- Levofloxacin 500 mg oral tablet, one tablet daily while the neutrophil count is below 0.5 **S**
- Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours as needed for nausea **S**
- Polyethylene glycol 3350, 17 g powder in a glass of water once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 110/66 mmHg; pulse 90 bpm; respirations 16/min; temperature 37 °C; oxygen saturation 97% on room air; weight 52.8 kg; BMI 19.9 kg/m². All vital signs are synthetic.

White cell count: 0.6 10*3/uL (low); Absolute neutrophil count: 0.2 10*3/uL (low); Hemoglobin: 8.9 g/dL (low); Platelets: 31 10*3/uL (low); Blood blasts (smear): 0%; Bone marrow blasts: 3%; Sodium: 138 mmol/L; Potassium: 3.9 mmol/L; Creatinine: 0.79 mg/dL; eGFR: 87 mL/min/1.73 m²; LDH: 196 U/L; ALT: 31 U/L. All results are synthetic.

## Change since baseline

- White cell count: 2.1 10*3/uL (low) at baseline, 0.6 10*3/uL (low) at this visit **S**
- Absolute neutrophil count: 0.6 10*3/uL (low) at baseline, 0.2 10*3/uL (low) at this visit **S**
- Hemoglobin: 8.4 g/dL (low) at baseline, 8.9 g/dL (low) at this visit **S**
- Platelets: 38 10*3/uL (low) at baseline, 31 10*3/uL (low) at this visit **S**
- Blood blasts (smear): 12% (high) at baseline, 0% at this visit **S**
- Sodium: 139 mmol/L at baseline, 138 mmol/L at this visit **S**
- Potassium: 4 mmol/L at baseline, 3.9 mmol/L at this visit **S**
- Creatinine: 0.78 mg/dL at baseline, 0.79 mg/dL at this visit **S**
- eGFR: 88 mL/min/1.73 m² at baseline, 87 mL/min/1.73 m² at this visit **S**
- LDH: 412 U/L (high) at baseline, 196 U/L at this visit **S**
- ALT: 22 U/L at baseline, 31 U/L at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Tired but well; weight 52.8 kg; temperature 37.0 °C |
| Mouth | No ulcers or thrush |
| Respiratory | Fine crackles at the right apex, unchanged |
| Skin | Injection sites healed; no rash |
| Abdomen | Soft, non-tender |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Acute myeloid leukemia, day 22 of cycle 1** (C92.00). The day-22 marrow is hypocellular (about 10 percent) with 3 percent blasts: a leukemia-free marrow. Flow cytometry finds measurable residual disease at 0.6 percent. Neutrophils 0.2 and platelets 31 x10^3/uL: as planned when the marrow is clear, venetoclax is stopped today to let the counts recover, and the next cycle will begin when neutrophils are at least 0.5 and platelets at least 50, with venetoclax for 21 days. **S**
   - Stop venetoclax today; continue posaconazole, acyclovir and levofloxacin while neutropenic.
   - Stop allopurinol; tumor lysis risk has passed.
   - Blood count twice weekly; response review when counts recover.
   - Posaconazole trough level with the next blood count.
2. **Nausea, vomiting and constipation, resolved** (R11.2). Settled. **S**
   - Ondansetron and laxatives as needed only.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count with differential and smear | At diagnosis; two to three times a week during induction; before each cycle | Completed today | White cells 0.6, neutrophils 0.2, hemoglobin 8.9 g/dL, platelets 31 x10^3/uL; no blasts on the smear |
| Laboratory | Bone marrow: morphology, flow cytometry, cytogenetics, molecular panel | At diagnosis; day 21 to 28 of cycle 1; then as response and transplant planning require | Completed today | Day-22 marrow: about 10% cellular, 3% blasts; flow MRD 0.6%: leukemia-free marrow; venetoclax stopped for count recovery |
| Laboratory | Chemistry: electrolytes, creatinine, calcium, phosphate, uric acid, LDH, liver tests | At diagnosis; during venetoclax ramp-up for tumor lysis; then weekly in cycle 1 and before each cycle | Completed today | Sodium 138, potassium 3.9 mmol/L; creatinine 0.79 mg/dL, eGFR 87; LDH 196 U/L; ALT 31 U/L |
| Medication safety | Azole safety: posaconazole interactions (venetoclax dose), liver tests, QTc, trough level | At start; liver tests weekly; trough level after about a week of dosing; QTc with any added QT-prolonging drug | Deferred | Missed: the posaconazole trough level due after about a week of dosing was not drawn. No harm judging by the absence of fever or fungal infection, normal liver tests, and a QTc of 446 ms on day 11. Corrective action: trough level with the next blood count, and added to the cycle order set |
| Medication safety | Transfusion support: thresholds, irradiated and leukoreduced products | At each blood count | Completed today | No transfusion needed today |
| Self-management | Infection prophylaxis and the fever plan | Throughout neutropenia | Completed today | No fever; prophylaxis taken as prescribed; fever plan reviewed |
| Referral | HLA typing and allogeneic transplant evaluation | During cycle 1 | Completed today | Seen once at the transplant center; unrelated donor search under way |
| Referral | Specialist palliative care: symptoms, prognosis, goals and values | At every visit | Completed today | Second palliative care visit last week; symptoms controlled |
| Self-management | Occupational exposure history and dose records | Until the records are received | Due | Records not yet received; second request sent |

## Goal progress

- Diagnosis, classification and a treatment decision within two weeks of the first visit. Outcome by 1955-09-28: Marrow two days after the first visit; genetics back and treatment started on day 14. **S**
- Complete cycle 1 without tumor lysis, invasive fungal infection, or bleeding. In progress; target 1955-10-30. **S**
- Remission on the response assessment after cycle 1 (ELN 1951 complete remission, or complete remission with partial hematologic recovery). In progress; target 1955-10-30. **S**
- Her own goals and values recorded and her symptoms controlled with the palliative care team from the first cycle. Outcome by 1955-09-28: Seen by the palliative care team on day 1; goals recorded; symptoms reviewed at every visit. **S**
- Her occupational dose records obtained and the exposure history documented. In progress; target 1955-10-30. **S**

## Medication changes

- Stopped: Venetoclax 10 mg oral tablet, cycle 1: 10 mg on day 1 and 20 mg on day 2, then two tablets (20 mg) daily with the 50 mg tablet from day 4 (70 mg a day, reduced for posaconazole) **S**
- Stopped: Venetoclax 50 mg oral tablet, cycle 1: one tablet alone on day 3 (50 mg), then one tablet daily with two 10 mg tablets from day 4 (70 mg a day) **S**
- Stopped: Allopurinol 300 mg oral tablet, one tablet daily for tumor lysis prophylaxis during cycle 1 **S**
- Stopped: Sennosides 8.6 mg oral tablet, two tablets at bedtime **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 5.2026 (2026), National Comprehensive Cancer Network
- Döhner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022 (PMID 35797463) (2022), European LeukemiaNet (Blood)
- DiNardo CD, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia (VIALE-A). N Engl J Med 2020 (PMID 32786187) (2020), New England Journal of Medicine
- NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections (2026), National Comprehensive Cancer Network
- Taplitz RA, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: ASCO and IDSA Clinical Practice Guideline Update (PMID 29461916) (2018), American Society of Clinical Oncology and Infectious Diseases Society of America (Journal of Clinical Oncology)
- Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024 (PMID 38748941) (2024), American Society of Clinical Oncology
- Carson JL, et al. Red Blood Cell Transfusion: 2023 AABB International Guidelines. JAMA 2023 (PMID 37824153) (2023), Association for the Advancement of Blood and Biotherapies (JAMA)
- Kaufman RM, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015 (PMID 25383671) (2015), AABB (Annals of Internal Medicine)
- 10 CFR 19.13, Notifications and reports to individuals (radiation exposure reports on request) (2026), U.S. Nuclear Regulatory Commission (Electronic Code of Federal Regulations)
- 29 CFR 1910.1096, Ionizing radiation (records of exposure and disclosure to employees) (2026), Occupational Safety and Health Administration

## Follow-up

- Blood count twice weekly with the posaconazole level. Response review and the cycle 2 decision when counts recover. Emergency department at once for a temperature of 38.0 °C or more. **S**
- Next scheduled visit 1955-10-26: periodic adult preventive visit during AML therapy. **S**
